Celon Pharma at BIO Digital 2020

Company representatives will participate  in one of the largest partnering conferences for the biopharmaceutical industry, which will be held on 8-11.06.2020. During online sessions they will present selected projects in the therapeutic areas such as: neuropsychiatry, inflammatory and metabolic diseases. If you are interested in meeting with the Company, please contact: [email protected] More information aboutRead more »

The largest and most advanced innovative pipeline in Poland with the potential for global commercialisation, supported by a favourable domestic and worldwide dynamic of product sales.

Net profit of over PLN 9.4 million in Q1 2020, increase in domestic sales by 16% and by 2% in export sales, compared to the same period in 2019. In the first quarter of 2020, the value of sales revenues amounted to PLN 30.9 million. It included the product sales in Poland, which accounted forRead more »

4th project in clinical development – GPR40 with the consent of URPLWMiPB to launch the study

On 29 April 2020, we have received a positive decision from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) regarding an innovative GPR40 receptor agonist – CLP207280. The clinical programme will be conducted in the treatment of metabolic diseases, including type II diabetes and diabetic neuropathies. The aim ofRead more »

Celon Pharma signs an agreement with the National Centre for Research and Development (NCRD) for subsidising the Company’s subsequent projects

“Serotonergic analgesic therapy based on5-HT7 receptor agonist (STEP7)” is a project constituting a part of our innovative pipeline, implemented in the field of neuropsychiatry. The goal of the STEP7 project is the development and clinical evaluation up to and including phase II studies, of a first-in-class 5-HT7 receptor agonist as an analgesic used in treatmentRead more »

Celon Pharma S.A. at the JP Morgan Investor Conference 2020

This year’s conference will be held between 13 and 16 January 2020 in San Francisco. Representatives of the Company’s Management Board will participate in the event. Maciej Wieczorek, CEO of Celon Pharma S.A.: This year, we are focusing on continuing the talks regarding a partnership agreement for esketamine DPI. The schedule of the phase IIRead more »

Innovators’ Breakfast with Celon Pharma S.A.

Dr. Maciej Wieczorek participated in the Innovators’ Breakfast at the invitation of the Ministry of Science and Higher Education and the National Centre for Research and Development. The purpose of the meeting was to inaugurate the “Fast Path” contest, but also to discuss the directions of the development of innovative economy in 2020 and theRead more »

Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen

  During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development. During the Congress, the Clinical Department representatives will present the results in a poster session which will takeRead more »

Celon Pharma – leader of the European Life Science training project

Celon Pharma became the leader of a European training project concerning the so-called hard skills, addressed to scientists, students, start-ups and entrepreneurs from all over Europe. The project is implemented in cooperation with the Medical University in Łódź, University of Navarra and Universidade de Evora, within the EIT Health network. Maciej Wieczorek, CEO of CelonRead more »

Valzek – drug status update

By way of decisions of the Chief Pharmaceutical Inspectorate of 6/06/2019, the following drug batches mentioned therein – Valzek 80mg and Valzek 160mg – were re-approved for marketing, as a result of confirming their compliance with quality requirements for the applicable substance valsartan, determined by the regulators. Based on these decisions, batches of Valzek markedRead more »